Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q9DK
|
||||
| Former ID |
DAP000339
|
||||
| Drug Name |
Nizatidine
|
||||
| Synonyms |
Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acid-reflux disorders [ICD9: 530.81; ICD10:K21] | Approved | [1], [2] | ||
| Therapeutic Class |
Antiulcer Agents
|
||||
| Company |
Eli Lilly
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H21N5O2S2
|
||||
| InChI |
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
|
||||
| InChIKey |
SGXXNSQHWDMGGP-IZZDOVSWSA-N
|
||||
| CAS Number |
CAS 76963-41-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9479, 7847506, 7980136, 10047729, 11112849, 12012865, 14801956, 26719892, 36077514, 46386765, 46507554, 48395159, 48416335, 49648463, 49968698, 57352747, 80039644, 85175204, 85209480, 92308159, 92308434, 92711372, 93166919, 103091650, 103157346, 103189241, 111634652, 117377111, 117480196, 119526527, 124658842, 124801333, 124882685, 126630925, 131269073, 131326051, 134337651, 135011516, 135692320, 137005454, 142971063, 144075999, 144089140, 152040062, 160963930, 172080209, 177748315, 178103822, 179116550, 179148990
|
||||
| SuperDrug ATC ID |
A02BA04
|
||||
| SuperDrug CAS ID |
cas=076963412
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H2 receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gastric acid secretion | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Histamine H2 receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Intracellular Signalling Through Histamine H2 Receptor and Histamine | ||||
| Gastric Acid Production | |||||
| Reactome | Histamine receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075616. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7248). | ||||
| REF 3 | Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy? J Gastrointest Surg. 2009 Mar;13(3):432-7. Epub 2008 Nov 1. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.